STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.

CLL GLI1 STAT3 apoptosis transcription

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
02 Mar 2021
Historique:
received: 02 10 2020
accepted: 26 01 2021
entrez: 22 3 2021
pubmed: 23 3 2021
medline: 23 3 2021
Statut: epublish

Résumé

The glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces GLI1 expression in GLI1-unmutated CLL cells is unknown. Because signal transducer and activator of transcription 3 (STAT3) is constitutively activated in CLL cells and sequence analysis detected putative STAT3-binding sites in the GLI1 gene promoter, we hypothesized that STAT3 induces the expression of GLI1. Western immunoblotting detected GLI1 in CLL cells from 7 of 7 patients, flow cytometry analysis confirmed that CD19+/CD5+ CLL cells co-express GLI1 and confocal microscopy showed co-localization of GLI1 and phosphorylated STAT3. Chromatin immunoprecipitation showed that STAT3 protein co-immunoprecipitated GLI1 as well as other STAT3-regulated genes. Transfection of CLL cells with STAT3-shRNA induced a mark decrease in GLI1 levels, suggesting that STAT3 binds to and induces the expression of GLI1 in CLL cells. An electromobility shift assay confirmed that STAT3 binds, and a luciferase assay showed that STAT3 activates the GLI1 gene. Transfection with GLI1-siRNA significantly increased the spontaneous apoptosis rate of CLL cells, suggesting that GLI1 inhibitors might provide therapeutic benefit to patients with CLL.

Identifiants

pubmed: 33747356
doi: 10.18632/oncotarget.27884
pii: 27884
pmc: PMC7939524
doi:

Types de publication

Journal Article

Langues

eng

Pagination

401-411

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright: © 2021 Rozovski et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.

Références

Mech Dev. 1997 Oct;67(2):111-23
pubmed: 9392510
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
J Immunol. 2019 Dec 1;203(11):3078-3085
pubmed: 31645416
J Invest Dermatol. 2012 Jul;132(7):1877-85
pubmed: 22418867
Am J Respir Cell Mol Biol. 2013 Jun;48(6):703-10
pubmed: 23371063
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Blood. 2014 Jun 12;123(24):3797-802
pubmed: 24778152
PLoS One. 2010 Jul 29;5(7):e11859
pubmed: 20686606
Cell Cycle. 2007 Nov 1;6(21):2640-9
pubmed: 17912034
Cell Commun Signal. 2018 Mar 20;16(1):11
pubmed: 29558958
Mol Med. 1999 Jul;5(7):432-56
pubmed: 10449805
Mol Cancer Res. 2008 Dec;6(12):1928-36
pubmed: 19074837
Oncotarget. 2018 Sep 14;9(72):33710-33718
pubmed: 30263097
J Clin Invest. 2011 Jan;121(1):148-60
pubmed: 21183792
Exp Dermatol. 2006 Sep;15(9):667-77
pubmed: 16881963
Mol Cancer Res. 2014 Sep;12(9):1267-82
pubmed: 24836891
mBio. 2015 May 26;6(3):e00686-15
pubmed: 26015501
Blood. 2015 Jun 11;125(24):3747-55
pubmed: 25931585
Mol Cancer Res. 2015 May;13(5):944-53
pubmed: 25733697
Oncotarget. 2018 Apr 20;9(30):21268-21280
pubmed: 29765537
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Mol Cancer Res. 2017 May;15(5):610-618
pubmed: 28130399
Semin Cancer Biol. 2016 Aug;39:40-8
pubmed: 27491692
Blood. 2019 Jun 20;133(25):2651-2663
pubmed: 30923040
Clin Cancer Res. 2010 Sep 1;16(17):4382-91
pubmed: 20534739
Nat Rev Neurosci. 2002 Jan;3(1):24-33
pubmed: 11823802
Oncogene. 2018 May;37(19):2502-2514
pubmed: 29449694
Hematology. 2004 Aug;9(4):279-86
pubmed: 15621735
Nat Rev Genet. 2009 Dec;10(12):845-58
pubmed: 19920852
Blood. 2010 Apr 8;115(14):2852-63
pubmed: 20154216
J Clin Invest. 1997 Dec 15;100(12):3140-8
pubmed: 9399961
Dis Model Mech. 2016 Feb;9(2):105-14
pubmed: 26839398
PLoS One. 2013 Jun 04;8(6):e64678
pubmed: 23750211
J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):163-73
pubmed: 17623270
JCI Insight. 2017 Jan 26;2(2):e89904
pubmed: 28138560
Best Pract Res Clin Haematol. 2007 Sep;20(3):399-413
pubmed: 17707829

Auteurs

Uri Rozovski (U)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tiqva, and The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

David M Harris (DM)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ping Li (P)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zhiming Liu (Z)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Preetesh Jain (P)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Taghi Manshouri (T)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ivo Veletic (I)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alessandra Ferrajoli (A)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Prithviraj Bose (P)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Phillip Thompson (P)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Nitin Jain (N)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Srdan Verstovsek (S)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

William Wierda (W)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael J Keating (MJ)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zeev Estrov (Z)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Classifications MeSH